Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 2018-2023

  Goey, S H ^a   Gratama, J W ^a   Primrose, J N ^b   Ward, U ^b   Mertelsmann, R H ^c   Osterwalder, B ^d   Verweij, J ^a   Stoter, G ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Roche Intl Clinical Research Center   (France)

Author keywords

5 fluorouracil; Colorectal cancer; Interferon alpha; Interleukin 2

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; INTERLEUKIN 2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LYMPHOCYTE; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030457151     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.670     Document Type: Article

References (30)

1. ATZPODIEN J, KIRCHNER H, HÄNNINEN EL, MENZEL T, DECKERT M, FRANZKE A, SCHOMBURG A AND POLIWODA H. (1994). Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon. Oncology, 51, 273-275.
2. BERENDT MJ AND NORTH RJ. (1980). T-cell-mediated suppression of anti-tumour immunity: an explanation for progressive growth of an immunogenic tumour. J. Exp. Med., 151, 69-81.
3. CAMERON RB, MCINTOSH JK AND ROSENBERG SA. (1988). Synergistic antitumour effects on combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res., 48, 5810-5817.
4. CASCINU S, DEL FERRO E, FEDELI A, GRIANTI C, FOGLIETTI G, OLIVIERI Q. (1993). Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. Cancer Res., 53, 5429-5432.
5. CHIKHALA NF, LEWIS I, ULCHAKER J, STANLEY J, TUBBS R AND FINKE JH. (1990). Interactive effects of α-interferon A/D and interleukin-2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res., 50, 1178-1182.
6. CORFU-A STUDY GROUP (1995). Phase III randomized study of two Fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J. Clin. Oncol., 13, 921-928.
7. ELIAS AND CRISMAN HA. (1988). Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res., 48, 4868-4873.
8. FELDMAN M AND EISENBACH L. (1991). MHC class-I genes controlling the metastatic phenotype of tumour cells. Semin. Cancer Biol., 2, 337-346.
9. GRATAMA JW, BRUIN RJ, LAMERS CHJ, OOSTEROM R, BRAAKMAN E, STOTER G AND BOLHUIS RLH. (1993). Activation of the immune system of cancer patients by continuous i.v. recombination interleukin-2 (rIL-2) therapy is dependent of dose and schedule of rIL-2. Clin. Exp. Immunol., 92, 185-193.
10. GRATAMA JW, SCHMITZ PIM, GOEY SH, LAMERS CHJ, STOTER G AND BOLHUIS RLH. (1996). Modulation of immune parameters in patients with metastatic renal cell cancer receiving combination immunotherapy (IL-2, IFN-α and autologous IL-2-activated lymphocytes). Int. J. Cancer, 65, 152-160.
11. GRESSER I. (1989). Antitumour effects of interferon. Acta Oncol., 28, 347-353.
12. HEIDELBERG C. (1957). Fluorinated pyrimidines, a new class of tumour inhibitory compound. Nature, 179, 663.
13. HEYS SD, ERANIN O, RUGGERI EM, PEIN F, RAINER H AND OSKAM R. (1995). A phase III study of recombinant interleukin-2, 5-Fluorouracil and leucovorin versus 5-Fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur. J. Cancer, 31A, 19-25.
14. HILL M, NORMAN A, CUNNINGHAM D, FINDLAY M, WATSON M, NICOLSON V, WEBB A, MIDDLETON G, AHMED F, HICKISH T, NICOLSON M, O'BRIEN M, IVESON T, IVESON A AND EVANS C. (1995a). Impact of protracted venous infusion fluorouracil with or without Interferon Alfa-2b on tumour response, survival, and quality of life in advanced colorectal cancer. J. Clin. Oncol., 13, 2317-2323.
15. HILL M, NORMAN A, CUNNINGHAM D, FINDLAY M, NICOLSON V, HILL A, IVESON A, EVANS C, JOFFE J, NICOLSON M AND HICKISH T. (1995b). Royal Marsden phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J. Clin. Oncol., 13, 1297-1302.
16. KEMENY N, YOUNES A, SEITER R, KELSEN D, SAMMARCO P, ADAMS L, DERBY S, MURRAY P AND HOUSTON C. (1990). Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer, 66, 2470-2475.
17. KÖHNE CH, WILKE H, HECKER H, SCHÖFFSKI P, KÄUFER C AND RAUSCHECKER H. (1995). Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann. Oncol., 6, 461-466.
18. MARINCOLA FM, WHITE DE, WISE AP AND ROSENBERG SA. (1995). Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J. Clin. Oncol., 13, 1110-1122.
19. MIYOSHI T, OGAWA S, KANAMORI T, NOBUHARA M AND NAMBA M. (1983). Interferon potentiates cytotoxic effects of 5-fluoruoracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett., 17, 239-247.
20. MOERTEL CG. (1994). Chemotherapy for colorectal cancer. N. Engl. J. Med., 330, 1136-1142.
21. ONODERA H, SOMERS SS AND GUILLOU PJ. (1990). Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. Br. J. Cancer, 62, 1042-1046.
22. PAZDUR R, AJANI JA, PATT YZ, WINN R, JACKSON D, SHEPARD B, DUBROW R, CAMPOS L, QUARAISHI M, FAINTUCH J, ABBRUZZESE JL, GUTTERMAN J AND LEVEN B. (1990). Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J. Clin. Oncol., 8, 2027-2031.
23. RIDOLFI R, MALTONI R, RICCOBON A, FLAMINI E, FEDRIGA R, MILANDRI C, PEZZI L, VELOTTI F, SANTONI A AND AMADORI D. (1994). A phase II study of advanced colorectal cancer patients treated with combination 5-Fluorouracil plus Leucovorin and subcutaneous Interleukin-2 plus Alpha-Interferon. J. Chemother., 6, 265-271.
24. ROSENBERG SA, LOTZE MT, YANG JC, LINEHAN WM, SEIPP C, CALABRO S, KARP SE, SHERRY RM, STEINBERG S AND WHITE DE. (1989). Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7, 1863-1874.
25. SMITH MEF, BODMER WF AND BODMER JB. (1988). Selective loss of HLA-A, B, C locus products in colorectal adenocarcinoma. Lancet, 1, 823-824.
26. WADLER S, SCHWARTZ EL AND GOLDMAN M. (1988). Preclinical and clinical studies of 5 fluorouracil (FURA) and recombinant α-2a interferon (IFN) against gastrointestinal (GI) malignancies. Clin. Res., 36, 803A.
27. WADLER S, SCHWARTZ EL, GOLDMAN M, LYVER A, RADER M, ZIMMERMAN M, ITRI L, WEINBERG V AND WIERNIK PH. (1989). Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7, 1769-1775.
28. WEBER JS AND ROSENBERG SA. (1988). Modulation of murine tumour major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res., 48, 5818-5824.
29. WHO. (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. WHO: Geneva.
30. YANG JC, SHLASKO E, RITCHEY JL, LANDRY JG, WHITE DE AND ROSENBERG SA. (1993). Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. Eur. J. Cancer, 29A, 355-359.